Noom Expands Blood Testing, Gene Editing Targets Cholesterol, Retro Biosciences Surges

May 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes.

Today's top stories:

• Noom launches at-home biomarker kits measuring 17 markers with microneedle collection, finding 70% of users have high LDL cholesterol despite appearing healthy
• Scientists report single gene-editing infusion lowering LDL cholesterol by 62% with results maintained 18+ months, potentially replacing years of daily medication
• Retro Biosciences reaches $1.8B valuation backed by Sam Altman, entering human trials testing cellular cleanup process to combat neurodegeneration and age-related disease

More from Fitt:

Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital.

Subscribe to our newsletter → insider.fitt.co/subscribe

Work with our recruiting firm → https://talent.fitt.co/

Follow us on Instagram → https://www.instagram.com/fittinsider/

Follow us on LinkedIn → linkedin.com/company/fittinsider

Reach out → insider@fitt.co